Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	123.94	174.47	203.14	300.85	14.63
Short-Term Investments	1.47	83.87	175.75	44.46	0
Cash & Cash Equivalents	125.42	258.33	378.88	345.31	14.63
Cash Growth	-51.45%	-31.82%	9.72%	2259.99%	80.11%
Other Current Assets	3.96	7.26	3.51	3.77	0.13
Total Current Assets	129.38	265.59	382.39	349.09	14.76
Property, Plant & Equipment	33.39	38.41	40.96	1.95	1.49
Other Long-Term Assets	2.32	2.32	2.31	2.3	0.19
Total Long-Term Assets	35.71	40.73	43.27	4.25	1.68
Total Assets	165.08	306.33	425.66	353.33	16.44
Accounts Payable	22.94	5.26	4.03	3.44	1.26
Current Debt	4.72	4.61	3.89	0	0
Other Current Liabilities	23.44	18.22	20.8	7.53	1.1
Total Current Liabilities	51.1	28.09	28.72	10.97	2.36
Long-Term Debt	22.7	25.87	28.74	0	0
Other Long-Term Liabilities	0	0	0	0	0.04
Total Long-Term Liabilities	22.7	25.87	28.74	0	0.04
Total Liabilities	73.79	53.96	57.47	10.97	2.4
Total Debt	27.42	30.48	32.64	0	0
Debt Growth	-10.06%	-6.60%	-	-	-
Retained Earnings	-632.51	-396.57	-228.47	-79.18	-19.75
Comprehensive Income	0	-0.57	-0.27	-0.03	0
Shareholders' Equity	91.29	252.36	368.2	342.37	14.04
Net Cash / Debt	98	227.85	346.25	345.31	14.63
Net Cash / Debt Growth	-56.99%	-34.19%	0.27%	2259.99%	80.11%
Net Cash Per Share	1.64	4.38	6.80	23.99	5.99
Working Capital	78.28	237.51	353.67	338.12	12.4
Book Value Per Share	1.53	4.86	7.23	23.78	5.75

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).